Gatti, Milo; Giannella, Maddalena; Raschi, Emanuel; Viale, Pierluigi; De Ponti, Fabrizio, Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2021, 76, pp. 199 - 205 [articolo]
Gatti M.; De Ponti F.; Pea F., Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies, «CNS DRUGS», 2021, 35, pp. 345 - 384 [articolo]Open Access
Gatti, Milo; Pea, Federico, Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections, «CURRENT OPINION IN INFECTIOUS DISEASES», 2021, 34, pp. 737 - 747 [articolo]Open Access
Fusaroli M.; Raschi E.; Gatti M.; De Ponti F.; Poluzzi E., Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System, «FRONTIERS IN PHARMACOLOGY», 2021, 12, Article number: 740707, pp. 1 - 11 [articolo]Open Access
Gatti M.; De Ponti F., Drug Interactions with Contraceptives, in: Trends in Andrology and Sexual Medicine, Berlino, Springer Science and Business Media Deutschland GmbH, 2021, pp. 325 - 359 (TRENDS IN ANDROLOGY AND SEXUAL MEDICINE) [capitolo di libro]
Gatti M.; De Ponti F., Drug repurposing in the covid-19 era: Insights from case studies showing pharmaceutical peculiarities, «PHARMACEUTICS», 2021, 13, Article number: 302, pp. 1 - 23 [articolo]Open Access
Donker E.; Brinkman D.; Richir M.; Papaioannidou P.; Likic R.; Sanz E.J.; Christiaens T.; Costa J.; De Ponti F.; Gatti M.; Bottiger Y.; Kramers C.; Garner S.; Pandit R.; Van Agtmael M.; Tichelaar J., European List of Essential Medicines for Medical Education: A protocol for a modified Delphi study, «BMJ OPEN», 2021, 11, Article number: e045635, pp. 1 - 4 [articolo]Open Access
Conti N.; Gatti M.; Raschi E.; Diemberger I.; Potena L., Evidence and current use of levosimendan in the treatment of heart failure: Filling the gap, «DRUG DESIGN, DEVELOPMENT AND THERAPY», 2021, 15, pp. 3391 - 3409 [articolo]Open Access
Gatti M.; Raschi E.; De Ponti F., Fluoroquinolones and Aortic Disease, «JAMA INTERNAL MEDICINE», 2021, 181, pp. 880 - 881 [articolo]
Cojutti P.G.; Gatti M.; Rinaldi M.; Tonetti T.; Laici C.; Mega C.; Siniscalchi A.; Giannella M.; Viale P.; Pea F., Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization, «FRONTIERS IN PHARMACOLOGY», 2021, 12, Article number: 781892, pp. 1 - 11 [articolo]Open Access
Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor, Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, «VACCINES», 2021, 9, Article number: 19, pp. 1 - 13 [articolo]Open Access
Gatti M.; Turrini E.; Raschi E.; Sestili P.; Fimognari C., Janus kinase inhibitors and coronavirus disease (Covid)‐19: Rationale, clinical evidence and safety issues, «PHARMACEUTICALS», 2021, 14, Article number: 738, pp. 1 - 22 [articolo]Open Access
Gatti M.; Pea F., Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors, «EXPERT REVIEW OF CLINICAL PHARMACOLOGY», 2021, 14, pp. 583 - 599 [articolo]Open Access
Giannella M.; Malosso P.; Scudeller L.; Bussini L.; Rebuffi C.; Gatti M.; Bartoletti M.; Ianniruberto S.; Pancaldi L.; Pascale R.; Tedeschi S.; Viale P.; Paul M., Quality of care indicators in the MAnageMent of BlOOdstream infections caused by Enterobacteriaceae (MAMBOO-E study): state of the art and research agenda, «INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS», 2021, 57, Article number: 106320, pp. 1 - 9 [articolo]
